Biopharma Daily Stock Updates - 01/29/21

$XBI $152.88 (+0.82%) 📈


COVID:

$CYDY (+8.82%) - Chiral Pharma Corp. to Assist Philippine Physicians Apply for Compassionate Special Permit (CSP) to Access CytoDyn’s Leronlimab for COVID-19 Patients, as Philippines FDA Reviews Each Application for Approval to Sell Leronlimab for CSP Use


$AZN (-2.77%) - COVID-19 Vaccine AstraZeneca authorized for use in the EU


$BNTX (+6.31%) & $PFE (+0.14%) - Pfizer and BioNTech Publish Data on COVID-19 Vaccine-Induced Antibodies’ Ability to Neutralize SARS-CoV-2 U.K. Strain Pseudovirus in Cell Culture in Science


$HGEN (-1.97%) - Humanigen Completes Enrollment in Phase 3 Study of Lenzilumab in Hospitalized Patients with COVID-19


$RDHL (-4.54%) - RedHill Biopharma Announces Positive DSMB Futility Review for Phase 2/3 COVID-19 Study of Opaganib


PIPELINE:

$AMRN (+2.74%) - AMARIN RECEIVES POSITIVE CHMP OPINION FOR ICOSAPENT ETHYL FOR CARDIOVASCULAR RISK REDUCTION


$KPTI (+1.53%) - Karyopharm Receives Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma


$PBYI (-0.35%) - Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung Cancer at WCLC 2020


$AZN (-2.77%) - Datopotamab deruxtecan and Enhertu show promising early clinical activity in patients with advanced non-small cell lung cancer


$AZN (-2.77%) - Tagrisso extended disease-free survival regardless of prior adjuvant chemotherapy in early-stage EGFR-mutated lung cancer


FINANCIAL:

$CBIO (-1.40%) - Catalyst Biosciences Announces Closing of Public Offering of Common Stock


$RIGL (+4.60%) - Rigel Awarded $16.5 Million from U.S. Department of Defense for Phase 3 Clinical Trial of Fostamatinib in COVID-19 Patients


$OTLK (-23.35%) - Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $35.0 Million


0 comments

*Disclaimer: Information provided on bpiq.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Big Moversâ„¢ is a trademark of Amp Biotech Research, LLC

©2021 by Biopharm IQ. Website by Awaken Studio.

SITE